Boyle RG, O'Connor PJ, Pronk NP, Tan A Stages of change for physical activity, diet, and smoking among HMO members with chronic conditions. Am J Health Promot. 1998 Jan-Feb;12(3):170-5.
De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009 Sep;24(6):412-24. doi: 10.1016/j.eurpsy.2009.01.005. Epub 2009 Aug 13.
Fagiolini A, Chengappa KN, Soreca I, Chang J Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs. 2008;22(8):655-69. Review.
Glassman AH, Bigger JT Jr Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001 Nov;158(11):1774-82. Review.
Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry. 2009 Jul;66(7):713-20. doi: 10.1001/archgenpsychiatry.2009.61.
Mackin P, Bishop DR, Watkinson HM A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry. 2007 Jun 25;7:28.
Mitchell JE, Mackenzie TB Cardiac effects of lithium therapy in man: a review. J Clin Psychiatry. 1982 Feb;43(2):47-51.
Morriss R, Mohammed FA Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol. 2005 Nov;19(6 Suppl):94-101. Review.
Newcomer JW Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry. 2006;67 Suppl 9:25-30; discussion 36-42. Review.
O'Connor PJ, Sperl-Hillen J Clinical and public health implications of glycemic relapse in type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2007 Jan;3(1):10-1.
O'Connor PJ Electronic medical records and diabetes care improvement: are we waiting for Godot? Diabetes Care. 2003 Mar;26(3):942-3. Review.
Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry. 2007 Feb;64(2):242-9. Erratum in: Arch Gen Psychiatry. 2007 Jun;64(6):736.
Shah SU, White A, White S, Littler WA Heart and mind: (1) relationship between cardiovascular and psychiatric conditions. Postgrad Med J. 2004 Dec;80(950):683-9. Review.
Sowden GL, Huffman JC The impact of mental illness on cardiac outcomes: a review for the cardiologist. Int J Cardiol. 2009 Feb 6;132(1):30-7. doi: 10.1016/j.ijcard.2008.10.002. Epub 2008 Nov 11. Review.
Taylor V, MacQueen G Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatry. 2006 Jul;67(7):1034-41. Review.
Trangle M, Gary M, Paul G, Christensen R Minnesota 10 by 10. Reducing morbidity and mortality in people with serious mental illnesses. Minn Med. 2010 Jun;93(6):38-41.
Weiner M, Warren L, Fiedorowicz JG Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011 Feb;23(1):40-7. Review.
Wong CK, Tang EW, Herbison P, Birmingham B, Barclay L, Fu SY Pre-existent depression in the 2 weeks before an acute coronary syndrome can be associated with delayed presentation of the heart attack. QJM. 2008 Feb;101(2):137-44. doi: 10.1093/qjmed/hcm153. Epub 2008 Jan 10.
Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.